An appraisal of T cell subsets and the potential for autoimmune injury  by Kelly, Carolyn J. et al.
PERSPECTIVES IN BASIC SCIENCE
An appraisal of T cell subsets and the potential for autoimmune
injury
CAROLYN J. KELLY, YAACOV FRISHBERG, and DANIEL P. GOLD
University of California San Diego and the San Diego Veterans Administration Medical Center, San Diego, California, USA; the Shaare
Zedek Medical Center, Jerusalem, Israel; and The Sidney Kimmel Cancer Center, San Diego, California, USA
The initiation of T cell dependent immune responses requires
the T cell to utilize a heterodimeric cell surface antigen receptor
to recognize an antigenic peptide in association with major
histocompatibility complex (MHC) molecules on the surface of
antigen presenting cells (APCs). This is a necessary but insuffi-
cient signal for T cell activation. T cells must additionally receive
a costimulatory signal that can be delivered through a variety of
receptor-ligand pairs. Of these, the best characterized is the
CD28-B7 (CD80 and CD86) couple. It has been appreciated for
decades that the outcome of the T cell-APC interaction is highly
variable and can lead to different forms of immune responses. The
past decade has witnessed major advances in the definition of how
distinct lymphocyte functions are dictated by expression of distinct
cytokines, activation of defined signal transduction pathways, and,
most recently, expression of distinct transcription factors. The
production of ever increasing numbers of induced mutant mouse
strains has created new reagents in which to analyze the role of
particular cytokines or other proteins in defined immune re-
sponses. While the temptation remains to accomodate emerging
information into reductionist models of T cell dependent immu-
nopathology, it is our view that in vivo immune responses are
highly complex and regulated events that defy simple categoriza-
tion.
The goal of this review is to provide an overview of current
information relevant to how different types of T cell responses
develop and how such responses relate to the expression of
disease. Our review will focus in depth on the concept of a
“Th1-Th2” paradigm and how that relates to harmful versus
protective immune responses. We will briefly touch on the out-
come of costimulation of T cells via distinct receptor-ligand
couples, and the effect of a number of other defined cell surface
glycoproteins and cytokines on T cell responses. Relevant work in
model systems of inflammatory renal injury will be discussed
where appropriate.
POLARIZED T CELL RESPONSES: THE TH1 VS. TH2
PARADIGM
Over a decade has passed since initial studies by Mosmann et al
defined two distinct subsets of murine CD41 T cell clones based
on their ability to synthesize nonoverlapping profiles of cytokines
[1]. Since that time, there has been an enormous amount of work
examining the cellular and molecular basis for this polarization of
CD41 T cell responses as well as investigations into the relation-
ship between polarized CD41 T cell responses and immune
responses to infections and self antigens. In this section, we will
summarize some of this information. Figure 1 provides a sche-
matic outline for the information discussed in this section.
Th1 and Th2 CD41 T cells are defined primarily by cytokine
production
CD41 T cell clones, which produce interleukin (IL)-2, tumor
necrosis factor-b (TNF-b), and g-interferon (g-IFN) and mediate
DTH responses, are termed “Th1” clones, whereas those CD41
clones which express IL-4 and IL-5 and induce immunoglobulin
(Ig)G1 and IgE production by B cells are termed “Th2” cells [2].
Although these initial observations were made with long-term
cultured clones, subsequent studies established the existence of
similar subsets in vivo [3, 4]. Although the statement is frequently
made that Th1 and Th2 responses correspond to cell-mediated
and humoral immunity, respectively, in fact Th1-like CD41 T
cells can provide help for the production of some Ig isotypes, in
particular IgG2a in the mouse. The existence of discrete Th1 and
Th2 subsets in humans is more controversial, although evidence
exists for the paradigm in this setting as well [5].
Since the original description of Th1 and Th2 clones, additional
characterization of these populations has been performed. A third
subset, denoted “Th0” T cells, has been defined that produces a
mixture of the Th1 and Th2 cytokine patterns [6]. IL-6, IL-10, and
IL-13 have been added to the group of Th2 cytokines [7].
Although several cell-surface markers, including CD45 isoforms,
have been proposed as candidates to distinguish the Th1 and Th2
subsets, the stable definition continues to be based on cytokine
profiles and effector function. Two recent publications, however,
have provided evidence that Th1 and Th2 subsets additionally
exhibit distinct migratory capacities into tissues. These capacities
map with distinct cell surface receptor expression. Murine Th1
cells, but not Th2 cells, can bind to P- and E-selectin [8]. The
migration of these Th1 cells into inflamed sites can be blocked by
antibodies to E- and P-selectin. Human Th2 cells, on the other
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hand, express a high affinity receptor for the CC-chemokine
eotaxin, called CCR3 [9]. Eotaxin is a potent chemoattractant for
eosinophils and basophils. It is produced by phagocytes and
epithelial cells. Since Th2-like cytokines like IL-4 and IL-5 are
critical growth factors for eosinophils and basophils, the expression
of CCR3 on Th2 cells provides a mechanism for the recruitment of
this CD41 subset into sites of allergic inflammation.
Th1 and Th2 cells differentiate from a common precursor
under the influence of distinct cytokine influences
How does a T cell in vivo become a Th1 or a Th2 cell? Extensive
work performed using transgenic mice expressing a single T cell
antigen receptor supports the conclusion that there is a single
naive precursor population (expressing both g-IFN and IL-4) that
can give rise to cells committed to either the Th1 or Th2 effector
lineage [10]. The major in vivo factor that has been implicated in
directing naive CD41 cells to the Th1 or Th2 pathway is the
cytokine milieu.
IL-12 and g-IFN promote the expansion of Th1 cells [11, 12],
and g-IFN additionally blocks differentiation along the Th2
pathway. Studies supporting these conclusions have been per-
formed using polyclonal stimuli in vitro followed by restimulation
to induce cytokine expression and with TCR transgenic T cells
stimulated with their relevant antigen. They have additionally
been performed by administering IL-12 and g-IFN to intact
animals and studying the resultant populations.
IL-4 is the cytokine that has consistently demonstrated power-
ful effects in driving differentiation of ab CD41 T cells to the Th2
phenotype [13]. Studies utilizing mice deficient in specific cyto-
kines, be they genetic knockout mice or animals receiving neu-
tralizing antibodies to cytokines, have demonstrated profound
influences on Th phenotypes [14–16].
Fig. 1. A diagrammatic representation of T cell
differentiation between classical Th1 and Th2
pathways. Details of each step in this diagram
are in the text.
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What is the in vivo basis for distinct cytokine milieus? How
dominant or selective expression of g-IFN and IL-12, or IL-4 is
achieved in vivo is as yet unclear. The cellular sources of these
cytokines in vivo is focus of much investigation. There has been
enthusiasm for the participation of a unique subset of T cells, the
NK11 T cell, in polarizing CD41 cells to a Th2 response [17].
These T cells can recognize CD1, a family of MHC class I-like
glycoproteins, which consist of a 45 kDa heavy chain nonco-
valently associated with b2-microglobulin. The CD1 molecules
only display limited polymorphism, unlike the classical class I and
class II MHC molecules. They have been divided into two groups,
based on physiologic distribution and sequence [18]. The first
group (CD1a, CD1b, and CD1c) are expressed on professional
antigen presenting cells, immature thymocytes, and some B cells
[19]. These CD1 molecules can present glycolipid and lipid
antigens to ab TCR-expressing T cells [20]. The second group of
CD1 molecules (human CD1d and mouse CD1.1 and CD1.2) is
expressed on thymocytes, peripheral lymphocytes, intestinal epi-
thelial cells, and hepatocytes [21]. The natural ligands for this
group are under intense investigation. However, mouse CD1.1 is
recognized by NK11 T cells. Phenotypically these T cells are
unusual, expressing both natural killer receptors (NK1, Ly-49A,
Ly-40C) and T cell markers (intermediate levels of abTCR, and
frequently CD4). The TCR usage of these cells is restricted with
most using a single TCR alpha chain (Va14) paired with either
Vb2, Vb7, or Vb8.2 [22, 23]. NK11 T cells are rare among
thymocytes (approximately 0.5 to 1.0% of total) but enriched in
the liver and bone marrow, compromising 20 to 50% of these T
cell populations [23]. These T cells generate large amounts of IL-4
following in vivo stimulation with anti-CD3.
This latter observation has led to the hypothesis that one of the
in vivo functions of NK11 T cells may be to provide the early IL-4
burst that subsequently biases the immune response to differen-
tiation down the Th2 pathway. This hypothesis is supported
indirectly by the fact that some mouse strains (such as, SJL) that
express low numbers of NK11 cells do not demonstrate the early
IL-4 burst following anti-CD3 administration in vivo, nor do they
produce IgE in response to anti-IgD antibodies [24]. SJL and
NOD mice (the latter also have low numbers of NK11 T cells
[25]) both display increased susceptibility to a variety of autoim-
mune diseases. Reports in both experimental and clinical autoim-
mune diseases have described decreased numbers of NK11 T cells
with disease progression [26, 27]. Finally, in vivo treatment with an
antibody to the dominant NK11 T cell TCR alpha chain (Va14)
accelerates murine lupus [26]. However, in mice made genetically
deficient in CD1, NK11 T cells are severely reduced in numbers,
and early IL-4 burst is missing, yet the CD12/2 mice generate IgE
normally in response to anti-IgD challenge, and they can mount
Th2-like recall responses [19, 28]. Since the impact of the mixed
genetic background of the knockout mice on these read-out assays
is as yet unclear, it is too soon to definitively rule out an important
role for NK11 T cells in driving Th2 responses. It should
additionally be noted that NK11 T cells can also express g-IFN,
but their role in Th1 responses is unexplored [29].
An alternative pathway to early IL-4 expression has been
recently described and involves the stimulation of naive T cells by
APC-derived IL-6 to make IL-4 [30]. Mast cells and basophils can
additionally be induced to make IL-4 following cross-linking of Fc
receptors by IgG or IgE [31, 32]. Finally, a recent study investi-
gating the Th2-polarized response of CD41 T cells from Balb/c
mice infected with Leishmania major, has strongly implicated a
subset of CD41 T cells in the generation of an early IL-4 “burst”
resulting in commitment down the Th2 effector pathway. These
cells are of additional interest since they express a highly re-
stricted ab TCR (Vb4, Va8) [33]. Th2 polarization in the
Leishmania major system additionally appears to be independent
of NK1.11 T cells [34]. In the aggregate, these studies underscore
the complexities of polarization of the CD41 Th response and the
potential for distinct mechanisms of regulation in different model
systems.
Classic antigen-presenting cells are the likely source of IL-12,
which initiates Th1 effector responses. IL-12 is a 70 kDa het-
erodimer comprised of two covalently linked proteins (p40 and
p35). The genes encoding both components must be expressed
within the same cell to produce the heterodimer. Although the
p35 gene is transcribed in many cell types, p40 gene expression is
more highly restricted and tightly regulated. B cells, adherent
monocytes, dendritic cells and skin Langerhans cells produce
amounts of IL-12, which are likely important in directing the
differentiation of CD41 T cells. A variety of other cell types,
including some cells not traditionally regarded as classical APCs
or as involved in the innate immune response, likely can also
express IL-12 in culture under defined conditions. The in vivo
significance of these observations has not yet been fully clarified.
IL-12 acts directly on undifferentiated T cells and provides an
early stimulus for natural killer cells to produce gIFN [35].
The Th1 and Th2 phenotypes involve the activation of distinct
signal transduction pathways and transcription factors
How do distinct cytokines generate intracellular signals that
result in CD41 T cell polarization? IL-4 and IL-12 both activate
members of a group of latent transcription factors termed signal
transducers and activators of transcription (Stat). For example,
IL-4 activates Stat-6 in Th2 cells and Stat-6 deficient mice cannot
generate Th2 responses [36]. IL-12, on the other hand, induces
the phosphorylation of Stat-4 in Th1 cells but not Th2 cells. Stat-4
deficient mice do not generate Th1 responses [37, 38]. The
complete connection from activation of different Stat proteins to
which genes are expressed in Th1 and Th2 cells is not yet clear.
However, within the past year, several transcription factors have
been identified to play critical roles in Th1 versus Th2 differenti-
ation. Using cDNA subtraction by representational difference
analysis, Zheng and Flavell recently identified the transcription
factor GATA-3 as the dominant species present in such an
analysis between normal Th1 and Th2 cells induced in vitro [39].
GATA-3 is selectively expressed both in differentiating and
effector Th2 cells, it is required for the transcription of all Th2
cytokine genes, and the loss of Th2 cytokine gene expression in
Th1 cells appears to be related to the down-regulation of
GATA-3. Transgenic mice that constitutively express GATA-3
under the control of the CD4 promoter demonstrate Th2 cytokine
gene expression in Th1 precursors [39]. This impressive body of
work stresses the importance of this transcription factor in
committing cells to differentiation along the Th2 pathway.
In complementary studies, recent work employed the combina-
tion of the T cell receptor transgenic system with mice lacking the
expression of the transcription factor interferon regulatory fac-
tor-1 (IRF-1) to determine the importance of IRF-1 in Th1 versus
Th2 differentiation [40, 41]. IRF-1 is a transcription factor
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induced by interferon (IFN)-a/b/g. The studies performed in this
system suggested that IRF-1 is essential for the development of
the Th1 response and that it functions in multiple cell types which
participate in the differentiation of Th1 CD41 T cells. T cells from
these mice exclusively undergo Th2 differentiation in vitro. The
animals demonstrate defects in macrophage function character-
ized by impaired IL-12 production. Their CD41 T cells are not
responsive to IL-12 and they have abnormal natural killer cell
activity [41].
Polarized T cell phenotypes display a complex relationship to
the pathogenesis of autoimmune disease
While the molecular mechanisms underlying the polarization of
CD41 Th cells are being meticulously delineated, the larger issue
of the relationship between these polarized responses and auto-
immunity continues to be more controversial. In this section, we
will outline some of the generic issues raised in trying to evaluate
polarized Th cell responses in the context of autoimmunity, and
give specific examples where appropriate.
A dominant paradigm for infectious disease models, in partic-
ular the immune response to Leishmania major, has been that
cell-mediated immunity critical for the defense against intracellu-
lar microorganisms is mediated by Th1-like T cells [42]. Resis-
tance to extracellular pathogens is generated most effectively by
activation of Th2-like cells. In some model systems of organ-
specific autoimmunity, there is a good correlation between the
preferential induction of Th1 T cells and the development of
autoimmune pathology with impaired organ function.
Experimental manipulations that examine the relevance of the
Th1-Th2 paradigm to organ-specific autoimmunity. How does one
experimentally examine the issue of whether the mediation of an
autoimmune disease is attributable to a polarized Th response?
Supportive evidence can be obtained by examining the cytokine
profiles of Ag-reactive T cells obtained from sites of immuniza-
tion, or, preferably, from the disease site. The need for isolation of
cells from disease foci and ex vivo culture has been obviated by the
use of sensitive in situ techniques for detection of cytokine mRNA
and intracellular cytokine proteins. Demonstrating organ pathol-
ogy and functional organ impairment following the adoptive
transfer of a T cell clone that displays polarized cytokine expres-
sion can provide evidence of relevance for immunopathology.
Failure of such a clone to cause disease, however, does not negate
the hypothesis, since cultured T cell clones may not traffic
normally in the naive host, and they may require other immune
cell types or microenvironmental factors only present in the
immunized or disease-prone animal.
Some investigators have tested the relevance of polarized
CD41 T cells to autoimmunity by employing maneuvers that lead
to a polarized response and examining whether such a maneuver
results in directionally consistent changes in disease expression.
Examples of this could include the administration of polarizing
cytokines, such as IL-12, g-IFN, or IL-4, or the administration of
neutralizing antibodies to such cytokines. Difficulties in the
interpretation of such studies include the obvious problem that
cytokine administration may trigger effector or regulatory events
relevant to disease expression in conjunction with, but unrelated
to, the observed polarization of the Th response. The major
technical problems with antibody administration center around
the duration of therapy required, the timing of the administration,
and the development of immune responses targeted to the
neutralizing antibody.
Genetically altered mice can be used theoretically to avoid
some of the above-described problems with either cytokine or
antibody infusion. For example, the incidence and severity of
collagen-induced arthritis are significantly reduced in IL-12
knockout mice. These animals also display decreases in IgG2a
responses to type II collagen (the immunogen) and depressed
collagen-induced secretion of g-IFN by splenocytes in vitro [43].
Yet it is frequently unclear what definitive conclusions can be
drawn from studies of autoimmunity in cytokine knockout mice.
The majority of cytokine knockouts generated to date are animals
in which the cytokine(s) is deleted from birth in all cells of the
animal. Given the well recognized redundancy in cytokine func-
tion, the failure of cytokine deletion to affect the course of an
autoimmune process does not establish that in the intact organism
that cytokine has no important role in the disease process. This
generic issue has been well summarized recently [44].
The course of experimental allergic encephalitis (EAE) in
various cytokine knockout animals provides instructive examples.
There is little controversy that Th1-like T cells are important to
the pathogenesis of EAE. The CD41 T cells that differentiate
following immunization to produce disease in both mice and rats
are Th1-like in cytokine expression. Th1-like T cell clones can
adoptively transfer disease into naive hosts. Multiple studies have
provided both direct and correlative evidence implicating TNF-a
and lymphotoxin (LT)-a in the immunopathogenesis of EAE.
Despite this, EAE develops normally in animals in whom both
TNF-a and LT-a are inactivated [45]. Gamma-IFN knockout
mice display heightened mortality when immunized to produce
EAE, rather than protection [46]. Such results may be related to
other cytokines substituting for the roles typically played by
TNF-a, LT-a, and g-IFN. Alternatively, cytokines such as g-IFN
may be subserving protective, rather than pathogenic roles that
have been underappreciated [47]. In the case of g-IFN, a strong
argument can be made for the ability of this cytokine to induce
nitric oxide synthesis through the cytokine inducible isoform and
thereby dampen pathogenic T cell responses (see below) [48].
Alternate forms of antigen presentation that protect the host from
induction of disease can lead to polarized T cell responses. The
phenomenology that alternate, “less immunogenic” means of
antigen presentation can elicit “tolerance” when the host is
subsequently challenged with antigen in an immunogenic form
has been established for years in the field of immunology.
Examples of this include preimmunization with the antigen of
interest in incomplete Freund’s adjuvant (IFA) or administering
the antigen orally, intranasally, or via the respiratory tract. When
the antigen of interest is the target of an autoimmune disease,
preimmunization in IFA or oral feeding can result in protection
from disease [49–51]. These alternate forms of antigen presenta-
tion appear to preferentially activate T cells expressing Th2-like
cytokine expression [50, 52]. Indeed, T cells expressing Th2-like
cytokines probably account for some of the phenomenology
previously attributed to suppressor T cells. Transforming growth
factor-b (TGF-b) appears to play a prominent role in the sup-
pression of disease mediated by these T cells [53]. Likewise, in
murine interstitial nephritis, an autoimmune disease dependent
on effector T cells, TGF-b plays an important role in the
suppression of disease seen following alternate antigen presenta-
tion [54–56].
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Th2 T cells can cause autoimmune disease in immunocompro-
mised hosts. Although a paradigm based on the ability of Th1-like
T cells to cause autoimmune disease and Th2-like cells to be
protective is appealing in its simplicity and symmetry, recent
studies suggest that the paradigm requires modification. For
example, augmented pathology, probably attributable to autoan-
tibodies, is demonstrable following immune deviation to a Th2-
like response in a model of encephalomyelitis [57]. In addition,
two recent publications have meticulously demonstrated that in
immunodeficient hosts, Th2 T cells can cause pathologic lesions
that histologically resemble allergic processes [58, 59]. Both
studies utilized a similar experimental design of taking T cells
bearing single antigen receptors from TCR transgenic mice,
culturing them in vitro with cytokines designed to polarize the T
cells along either the Th1 or Th2 pathway, and then transferring
these cells into either immunocompetent or immunodeficient
hosts. In one study the T cells were potentially encephalitogenic
[58] and in the other study, potentially diabetogenic [59]. Th2 cells
could transfer disease to NOD.scid mice, but not neonatal mice.
The lesions induced in the NOD.scid mice differed from lesions
induced by Th1 cells, in that the leukocytes infiltrated both the
endocrine and exocrine tissue, and the lesions were comprised
primarily of eosinophils and PMNs [59]. Treatment of NOD.scid
recipients of Th2 cells with anti-IL-10, but not anti-IL-4, antibod-
ies resulted in protection from this Th2 mediated lesion. In the
encephalomyelitis model system, Th2 cells initiated spinal cord
lesions characterized by unusually high numbers of PMNs and
mast cells compared to the mononuclear cell infiltrate typically
seen following transfer of Th1 cells. These Th2 cells could cause
disease following adoptive transfer into RAG-1 or TCR-a knock-
out mice, but not TCR-d knockout or immunocompetent mice
[58]. These studies heighten concern about the efficacy of thera-
pies based on immune deviation to a Th2 phenotype, particularly
in immunodeficient hosts. Since patients with autoimmune dis-
eases are frequently treated with immunosuppressive drugs, these
findings are potentially of direct clinical relevance.
Recent information regarding the Th1-Th2 paradigm in models
of renal disease
A variety of model systems in inbred rodents have been utilized
to examine the immunopathogenesis of various forms of glomer-
ulonephritis and interstitial nephritis. Several recent studies have
provided interesting findings with regard to the Th1-Th2 para-
digm in glomerulonephritis. A rapid proliferative glomerulone-
phritis can be produced in rodents if preimmunized (sensitized)
with sheep globulin in CFA and then injected intravenously with
sheep anti-mouse GBM globulin. The outcome of this protocol in
inbred mouse strains which classically display Th1- or Th2-
predominant immune responses is quite different. C57BL/6 mice
(Th-1 predominant) develop a crescentic glomerulonephritis fol-
lowing this protocol [60]. Involved glomeruli displayed significant
accumulations of T cells and macrophages. The severity of this
lesion can be diminished through the inhibition of g-IFN, sup-
porting the notion that Th1-like cells are important in the
immunopathogenesis [60]. Further support for the importance of
Th1-like cells in glomerular pathology has been provided recently
in the Heymann nephritis model of membranous nephropathy
[61].
In the murine model of crescentic glomerulonephritis described
above, treatment of C57BL/6 mice with IL-4 and/or IL-10, either
prior to or following the induction of the immune response
resulted in an improved functional outcome, diminished DTH
responses to sheep globulin, and diminished glomerular crescent
formation [62, 63]. The mechanism underlying this protective
effect correlated with selective inhibition of the Th1 response to
the antigen, when IL-4/IL-10 treatment was initiated prior to
induction of the immune response [62]. With initiation of treat-
ment after the establishment of injury, the mechanism of protec-
tion was less clear, as an analysis of the levels of IgG isotypes
between experimental groups and splenic production of g-IFN did
not support a deviation of the induced immune response to a
Th2-predominant form [63].
Although treatment with IL-4 and IL-10 was protective in a
mouse strain selected on the basis of its propensity to display
Th1-predominant immune responses, IL-10 alone was ineffective
in a related model of accelerated anti-glomerular basement
membrane (GBM) disease and crescentic glomerulonephritis in
rats [64]. The differences in outcome may relate to differing
protocols of administration (including the use of a single cytokine,
rather than IL-4 and IL-10), but may also reflect the genetic
background.
The outcome of the above described murine model is strikingly
different in Th2-biased (Balb/c) mice [65]. When Balb/c mice
sensitized to sheep globulin are given a subnephritogenic intrave-
nous dose of anti-mouse GBM globulin, they develop glomerular
deposition of Ig and complement, a significant neutrophil influx in
the glomeruli, and significant proteinuria. There are no significant
crescents or infiltrating T cells and macrophages in contrast to the
C57BL/6 mice. The lesion in the Balb/c mice can be attenuated by
complement depletion but not CD41 T cell depletion. The
reverse is true for C57BL/6 mice [65]. These studies support the
notion that the polarized Th responses may not map phenotypi-
cally with injury or protection but rather different forms of injury.
Another well studied model system in which autoimmune glomer-
ulonephritis develops in conjunction with a strong induced poly-
clonal Th2-like response is the HgCl2 induced model of glomer-
ulonephritis in the Brown Norway (BN) rat [66, 67]. Finally, in
some transgenic mice that overexpress IL-4, there is demonstrable
B cell hyperactivity, elevated IgG1 and IgE levels, and spontane-
ous glomerulonephritis with complement and antibody deposition
within the glomerulus [68]. This is in contrast to the protective
effect that constitutive expression of IL-4 has on the lupus-like
glomerulonephritis in (NZW x C57BL/6. Yaa)F1 mice [69].
While the argument can be made that many studies in trans-
genic and knockout mice “muddy the waters” by creating highly
artificial and unphysiologic scenarios, the bulk of emerging evi-
dence suggests that the Th1-Th2 (pathogenic-protective) para-
digm is too simplistic a model for understanding autoimmunity.
CO-STIMULATION OF T CELLS AND THE INITIATION OR
PROPAGATION OF AUTOIMMUNE PATHOLOGY
T cell proliferation is critically dependent on costimulation.
This section briefly reviews the process and recent studies on
costimulation in the context of autoimmunity are discussed.
The B7:CD28/CTLA-4 pathway
The major ligand receptor pairs functioning as co-stimulatory
molecules are the B7:CD28/CTLA-4 proteins. On the B7 side of
this interaction, there are two ligands, B7-1 (CD80) and B7-2
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(CD86), which are encoded by separate genes and are expressed
on different cells with different types of kinetics. Both of these
ligands can interact with each of two receptors expressed on T
cells, CD28 and CTLA-4. CD28 is expressed on both resting and
activated T cells, and following binding B7 molecules results in
co-stimulation of T cell activation, augmenting cytokine expres-
sion (particularly IL-2) and proliferation [70, 71]. CTLA-4 is only
expressed on activated T cells. It has a higher affinity for binding
with B7-1 and B7-2 than does CD28. Although initial reports
suggested that CTLA-4 was also involved in T cell activation, it is
now clear that engagement of CTLA-4 results in the inhibition of
IL-2 accumulation and T cell proliferation, especially when co-
stimulation by B7-1 or B7-2 is limiting [72, 73]. This inhibitory
effect of CTLA-4 engagement probably does not involve cell
death, either necrotic or apoptotic, but rather a failure of the T
cells to exit G1 [74]. These observations, from studies utilizing
naive T cells stimulated in vitro with varying combinations of
aCD3, aCD28, and aCTLA-4 or CTLA-4Ig, are well corrobo-
rated by the observations that blocking CTLA-4 in vivo results in
augmented anti-tumor immune responses and more severe auto-
immune disease [75–77], and by the severe lymphoproliferative
disease seen in mice made genetically deficient in CTLA-4 [78,
79]. (CTLA-Ig is a hybrid fusion protein that contains the
extracellular domain of CTLA-4 and an immunoglobulin Cg1
chain (human) or Cg2a chain (murine CTLA4Ig). It can neutral-
ize both B7-1 and B7-2. Recent studies have further extended the
role of the CTLA-4/B7 interaction to include the induction of
anergy in vivo. In these studies, the induction of functional
unresponsiveness in adoptively transferred TCR transgenic T cells
was blocked by the administration of CTLA-4Ig, or CTLA-4 mAb,
but not antibodies to CD28 [80].
The studies summarized above support the conclusion that the
outcome of the T cell-APC interaction will be critically dependent
on the nature of the costimulatory interaction, and not simply the
absence or presence of costimulation, as was previously hypothe-
sized. The cues that underlie a dominant B7-CD28 versus a
B7-CTLA-4 interaction are being intensively investigated. The
issues are complex given the potential for interaction between
both B7-1 and B7-2 with either CD28 or CTLA-4. In general, the
differences in B7-1 and B7-2 expression appear to be largely
temporal and in part cell specific. B7-2 is induced earlier than
B7-1 in most immune responses. Both molecules have been
described to be inducible on dendritic cells, Langerhans cells, B
cells, macrophages, and T cells. They are typically up-regulated
following macrophage activation and are up-regulated by g-IFN,
LPS, GM-CSF [reviewed in 81].
The relative role of the B7-1 versus B7-2 interaction with CD28
and CTLA-4 has been investigated in a variety of autoimmune
model systems. The variety of results obtained underscores the
complexities of these interactions. When murine CTLA4Ig is
injected into NZB/W F1 lupus prone mice, it blocks the produc-
tion of anti-DNA antibodies and prolongs life [82]. The role,
however, of B7-1 versus B7-2 is harder to generalize between
autoimmune models. For example in the lupus prone mice,
treatment with anti-B7-2 antibodies blocks production of some
anti-DNA antibodies, particularly IgG1 anti-DNA antibodies, but
was without effect on nephritis. Injection of anti-B7-1 had no
significant effect on anti-DNA antibodies or nephritis. However,
the injection of both anti-B7-1 and anti-B7-2 prevented produc-
tion of anti-DNA antibodies of all subclasses, blocked the devel-
opment of nephritis and resulted in a longer lifespan [83].
In the spontaneous model of insulin dependent diabetes in
non-obese diabetic mice, treatment with CTLA4-Ig or anti-B7-2
blocked the development of diabetes. Antibodies to B7-1 had no
protective effect [84]. The timing of this treatment was critical in
that only animals treated between 5 to 7 weeks of age were
protected. It is most intriguing that using NOD mice bred to the
CD28 knockout mouse, or NOD mice bred to a transgenic mouse
expressing CTLA-4Ig driven by a skin-specific keratin promoter,
the development and progression of spontaneous autoimmune
diabetes is promoted, rather than inhibited [85]. The authors
propose that this may be attributable to a preferential activation
of Th1-like rather than Th2-like autoreactive T cells early during
life. This unexpected experimental result raises another caution
flag regarding the interruption of this costimulatory pathway as a
treatment for autoimmune disease.
In murine experimental EAE, injection with anti-B7-2 antibod-
ies does not affect the severity of disease while injections with
anti-B7-1 do [86, 87]. CTLA4-Ig can prevent the onset of collagen
induced arthritis in BB rats [88]. These seemingly discrepant
results in different model systems would mitigate against being
able to broadly generalize the role of these interactive molecules
in autoimmune diseases and the types of immune response that
are generated. It seems possible that in each particular autoim-
mune disease the outcome of blocking both B7-1 and B7-2, or
either independently, may additionally depend on the types of
co-stimulatory molecules expressed on both professional and
non-professional antigen presenting cells within the target organ
of interest.
Role of the CD40-CD40L pathway
An additional co-stimulatory couple that is important in the
expression of autoimmune disease is the interaction between the
CD40 ligand on activated T cells and CD40, a molecule expressed
on B cells, antigen presenting cells and a whole host of other
parenchymal cells. Administration of blocking antibody to the
CD40 ligand can block the development of collagen arthritis [89],
the anti-DNA autoantibody response and renal disease in NZB/
WF1 mice [90], membranous nephropathy [91], autoimmune
oophoritis [92], and hapten induced colitis [93]. In genetically
manipulated mice, the absence of the CD40 ligand ameliorates
the expression of both EAE and the renal disease seen in MRL/lpr
mice [94, 95]. In many of these model systems, the presumed
mechanism of blockade of the CD40/CD40 ligand interaction has
been to block autoantibody production. It has also been noted
that impaired T cell responses can occur following interruption of
this interaction, be that through a neutralizing antibody or
through genetic deletion of the CD40 ligand. Blockade of the
CD40/CD40L interaction results in an impaired expression of
B7-1 and B7-2 on antigen presenting cells [96]. If B7-1 expressing
APCs are provided to CD40 ligand knockout mice, which express
T cell receptor specific for pathogenic epitope of myelin basic
protein, the animals can develop autoimmune disease although
they don’t in the absence of those antigen presenting cells [95].
Whether blocking of the CD40/CD40 ligand interaction blocks
autoimmune pathology through mechanisms other than blocking
autoantibody expression and indirectly through blocking T cell
activation from impaired B7-1 and B7-2 expression is a continued
area of investigation.
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Role of other cell surface moieties and mediators in dictating
outcomes of immune responses
While the Th2, Th1 paradigm and outcomes of co-stimulation
historically have assumed a prominent role in understanding the
development of “harmful” versus “harmless” immune responses,
there are a number of other cell surface glycoproteins and
secreted molecules whose expression may also be important in
defining a pathologic T cell response, and these are outlined
below.
Role of restricted T cell antigen receptor usage in autoimmune T
cell responses. The antigen receptor on the surface of most mature
T cells (TCR) is an integral membrane protein comprised of
heterodimeric a and b chains. The overall three dimensional
structure of the TCR is quite similar to that of immunoglobulin
(Ig), namely each a and b chain contains an amino terminal
variable region and a carboxy terminal constant region. However,
unlike immunoglobulin, which recognizes its ligand in the solution
phase either on the surface of B lymphocytes or as a secreted
molecule, the TCR only recognizes its ligand as a peptide
fragment of the protein antigen in association with major histo-
compatibility complex (MHC) class I and class II molecules on the
cell surface of other cells. In addition, the T cell receptor is not
present in the serum as a secreted molecule.
Diversity in antigen recognition by T cells is calculated to be as
high as for immunoglobulin due to the inherent diversity accom-
plished in the process of DNA rearrangements of the TCR
variable element genes during T cell development and due to the
random sorting of assembled TCR a and b chains [97].
The fact that T cell recognition occurs through clonally distrib-
uted TCR chains interacting with MHC-associated peptide frag-
ments of foreign or self proteins, raises the possibility that either
expression of unique TCR chains or presentation of unique
peptide fragments of self antigens could be factors in determining
susceptibility or resistance to autoimmune disease. Support for
the idea that unique TCR expression was associated with autoim-
munity initially came from observations in both the mouse and rat
models of experimental allergic encephalomyelitis (EAE). In both
rodent models, it was observed that the majority of T cells
responsive to the major encephalitogenic epitopes of myelin basic
protein (MBP) used a very limited repertoire of Va and Vb genes
[98–102]. Furthermore, strategies aimed at deleting or inactivat-
ing cells utilizing these families of TCR chains resulted in
protection from disease [98, 102–104].
Prompted by these studies, several groups have analyzed T cell
responses and TCR usage in a number of clinical autoimmune
disease settings. As an example, when studies were performed to
assess human T cell responses to MBP, no measurable differences
were observed in the frequency of MBP reactive T cells among
peripheral blood lymphocytes isolated from normal individuals
and patients with multiple sclerosis. Furthermore, there does not
appear to be any convincing differences in TCR usage among
normal individuals and patients with multiple sclerosis. There are
no convincing similarities in TCR usage among MBP reactive T
cell clones, isolated from multiple sclerosis (MS) patients, re-
sponding to the same epitope of MBP presented by the same
HLA-DR or -DQ molecule. One exception of note, however, is
the finding of Oksenberg and colleagues who described the
presence of a common TCR rearrangement in demyelinating
plaques isolated from CNS tissue of deceased MS patients [105].
These unique rearrangements were previously observed in human
and rat T cell clones recognizing similar regions of MBP. These
results suggest to the authors that certain epitopes of MBP are
being recognized in the CNS of patients with MS and perhaps by
T cells expressing a limited repertoire of TCR chains.
Overall, the conclusion from these studies and those in other
autoimmune settings is that the TCR per se is quite likely not
going to be a major susceptibility factor with respect to T cell
recognition of autoantigens [106]. However, it is equally likely that
the diversity of pathologic T cell responses in any individual or in
different individuals of similar HLA type and responding to
similar epitopes of an autoantigen, may in fact be limited.
If the TCR itself is not a determining factor in the selection of
a limited autoaggressive repertoire, then perhaps the repertoire of
HLA chains expressed by the individual predisposes towards
autoreative T cell development. Inheritance of particular alleles
of HLA genes has been associated with several autoimmune
diseases over the years. In addition, more recently it has become
appreciated that certain alleles are in fact protective towards the
development of certain autoimmune diseases. The best example
of this phenomenon is seen in the case of juvenile onset diabetes
[107]. Because HLA-associated peptide presentation to T cells is
critical for both T cell development in the thymus and T cell
activation in the periphery, several models have been proposed to
account for the apparent HLA linkage to autoimmune disease. It
is possible that certain peptide/MHC combinations can cause the
deletion of potentially autoreactive T cells maturing in the thymus
to a lesser or greater extent depending on amino acid differences
in the peptide binding domains of the HLA proteins. Since
autoreactivity to many self antigens can be demonstrated in
healthy individuals, it is unlikely that thymic deletion per se can
explain HLA linkage and autoimmune reactivity. Certainly, the
overall affinities of allowable self reactive antigen receptors could
differ depending on the nature of the peptide/MHC combinations
encountered during thymic T cell development and this difference
in affinity could be a determining factor in whether a potential
autoreactive T cell clone will be triggered or not. An alternative
hypothesis has suggested that certain alleles of HLA may have
higher affinities for certain self antigens and act as a “peptide
sink,” thereby removing or competing for particular self antigen
epitopes that if presented on a permissive HLA proteins would
evoke autoaggressive T cell responses [108]. This model could
help account for the observation of protective HLA alleles. A
slightly different version of this model would suggest that certain
HLA alleles could bind particular regions of an autoantigen with
high affinity, thereby altering the proteolytic processing of other
epitopes for which autoreactive T cells may exist [109]. Undoubt-
edly, all of these possibilities as well as others not mentioned will
prove to be true, in some form contributing to the overall
complexity of autoantigen TCR repertoire development and T
cell autoreactive responsiveness.
Role of the L-arginine:nitric oxide system in modulating T cell
responses. The quantities of nitric oxide (NO) generated through
the cytokine inducible isoform (iNOS, that is, inducible nitric
oxide synthase) are an important cytotoxic effector mechanism for
macrophages in the context of anti-tumor responses and for
eradicating intracellular parasites [110]. Since NO also has pro-
found antiproliferative effects on T cells [111], this system has the
potential to be one that alters the expression of autoimmune
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diseases dependent on activated T cells. We have recently inves-
tigated this hypothesis in two distinct models of organ-specific
autoimmune disease, anti-tubular basement membrane disease
with interstitial nephritis in the Brown Norway rat [112], and
experimental allergic encephalomyelitis in the Lewis rat [48]. In
each case the administration of a highly selective iNOS inhibitor,
L-N-(1-iminoethyl)lysine (L-NIL), led to a more severe immune
injury in animals immunized to produce disease. Interestingly, in
adoptive EAE, treatment of the recipients of myelin basic protein
reactive T cells with L-NIL led to less severe disease, suggesting
that the immunosuppressive effect of endogenously produced NO
may be predominantly on the induced T cell response, rather than
T cell-target cell interactions. L-NIL augments mitogen-induced
T cell proliferation and expression of g-IFN protein by mitogen
activated splenocytes [48]. L-NIL treatment of animals immu-
nized to produce interstitial nephritis leads to augmented IgG
responses to the immunogen and augmented expression of IL-2
and g-IFN (but not IL-4) within the diseased kidney [112]. In the
EAE model, treatment with L-NIL was sufficient to convert a
typically nonsusceptible strain (F344) to a susceptible strain.
These studies suggest that the intensity of cell-mediated immune
responses can be potently regulated by endogenously produced
nitric oxide. Since Th1-like cytokines such as g-IFN are important
for the up-regulation of iNOS during immune responses, the
antiproliferative and other immunosuppressive effects of NO may
form one limb of a critical feedback loop.
Lymphocyte migration and susceptibility to autoimmune disease.
The importance of lymphocyte migration out of the vasculature
and into the target organ as a susceptibility factor for the
expression of autoimmune disease has been relatively underex-
plored. Host-dependent expression of integrins, adhesion mole-
cules, chemoattractants, or their receptors may play critical roles
in determining whether potentially injurious effector cells are
capable of leaving the vasculature. Two recent studies provide
support for an important role of alpha-4 integrins expressed on T
cells in this process of T cell entry into target tissues [113, 114].
There is a growing interest in the role of chemokines in the
phenotypic expression of autoimmune kidney disease [115–119].
With the recent discovery of genetic polymorphisms in chemokine
receptors and the biologic importance of this trait in susceptibility
to HIV infection, it is possible that further work will identify these
chemokine receptor polymorphisms as additional susceptibility
factors for autoimmunity.
CONCLUSIONS
The immune system has evolved to deal with infectious organ-
isms. Major studies over the past ten years have provided an
enormous amount of information regarding the various pheno-
types of activated T cells, the cytokines they produce, the func-
tions they mediate, their requirements for activation, and how
they are differentially regulated. The characteristics which result
in a particular T cell response being “host beneficial” in the
context of infectious disease can be similar to those resulting in
autoimmune pathology. Autoimmunity is a complex process,
however, and it is clear that a simple Th1/Th2 paradigm does not
fully explain all forms of autoimmune tissue damage. Moreover,
although some rodent models of autoimmunity are more widely
studied than others, each model system has unique characteristics
that preclude generalizing conclusions from investigations into
disease pathogenesis or treatment in one or two model systems.
Given the available model systems, reagents, and major advances
in understanding T cell biology, the next decade will undoubtedly
witness innovative approaches to the therapy of autoimmune
disease.
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APPENDIX
Abbreviations used in this article are: APCs, antigen presenting cells;
CCR3, CC-chemokine eotaxin; EAE, experimental autoimmune enceph-
alomyelitis; g-INF, g-interferon; IFA, incomplete Freund’s adjuvant; Ig,
immunoglobulin; IL, interleukin; iNOS, inducible nitric oxide synthase;
IRF-1, interferon regulatory factor-1; L-NIL, L-N-(1-iminoethyl)lysine;
MBP, myelin basic protein; MHC, major histocompatibility complex; MS,
multiple sclerosis; NK, natural killer; NO, nitric oxide; STATs, signal
transducers and activators of transcription; TCR, T cell antigen receptor;
TNF-a, tumor necrosis factor-a; TNF-B, tumor necrosis factor-B.
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